Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Health Disparities
100%
Pediatric Leukemia
100%
Novel Targeted Therapy
100%
Casein Kinase 2
80%
B Cells
75%
Leukemia
75%
6-mercaptopurine (6-MP)
64%
Thiopurines
41%
CX-4945
38%
Latino children
33%
Hispanic Americans
33%
High Risk
25%
Transcriptional Regulator
25%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
25%
Leukemia Cells
21%
NT5C2
15%
Specific Inhibitor
12%
Biological Models
12%
Therapeutic Efficacy
12%
Childhood Cancer
12%
Combination Treatment
12%
Resistance to Treatment
12%
Synergistic Cytotoxic Effect
12%
Non-Hispanic White
12%
DNA-binding Proteins
12%
Cancer Disparities
12%
Worse Prognosis
12%
Resistance to Chemotherapy
12%
In Vivo Applications
12%
High Incidence
12%
Novel Therapies
12%
Socioeconomic Factors
12%
Transcriptional Repressor
12%
Patient-derived Xenograft
12%
Genetic Modification
12%
Adverse Prognosis
12%
Phosphorylation
12%
Biological Basis
12%
Increased Incidence
12%
DNA Binding Affinity
12%
Biological Rationale
12%
Mortality Rate
12%
Latino
10%
Pharmacology, Toxicology and Pharmaceutical Science
Health Disparity
100%
Leukemia
100%
Mercaptopurine
80%
Casein Kinase
60%
Casein Kinase II
60%
Acute Lymphoblastic Leukemia
25%
Carcinogenesis
9%
Cytotoxicity
9%
Chemotherapy Regimens
9%
DNA Binding Protein
9%
Childhood Cancer
9%
Mortality Rate
9%